Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026
Tailored Treatment of Functional Dyspepsia With Nortriptyline: A Multicenter, Double-Blind, Placebo-Controlled Trial.
Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bosch Daan H C A, Beckers Abraham B, Snijkers Johanna T W, Bosman Michelle H M A, Winkens Bjorn, Muris Jean W M, de Wit Niek, Brouwers Jacobus R B J, van Hee Koen, Clemens Cees H M, Haarhuis Bertram J T, Witteman Ben J M, Masclee Ad A M, Keszthelyi Daniel
Аннотация
BACKGROUND & AIMS: Low-dose tricyclic antidepressants may be effective for patients with functional dyspepsia (FD), although high-quality randomized controlled trials (RCTs) are limited. We aimed to investigate the efficacy of nortriptyline in an escalating low-dose regimen vs placebo in participants with FD following a genotype-guided pre-selection based on cytochrome P450 2D6 (CYP2D6), the primary enzyme responsible for nortriptyline metabolism.
METHODS: We conducted a multicenter, RCT of patients with FD in primary, secondary, and tertiary care. Sixty-nine participants were randomly assigned to nortriptyline (weeks 1-2: 10 mg; weeks 3-4: 25 mg; weeks 5-12: 50 mg) vs placebo for a 12-week treatment. The primary outcome was clinical response based on a decrease in FD symptoms of at least 30% compared with baseline, in 50% of the last 10 weeks of the treatment period.
RESULTS: The primary outcome showed no significant difference in response for nortriptyline compared with placebo (45% vs 58%; odds ratio [OR], 0.574; 95% confidence interval [CI], 0.211-1.560; P = .276). There was no significant difference in adverse events between the nortriptyline and placebo group. Nortriptyline plasma levels were significantly higher in responders compared with non-responders (13.0 μg/L; interquartile range [IQR], 12.0-16.0 vs 9.0 μg/L; IQR, 8.0-10.5; P = .003). The belief to have received nortriptyline showed a higher response rate than the belief to have received placebo (77% vs 36%; OR, 11.439; 95% CI, 2.138-61.201; P = .004).
CONCLUSIONS: Nortriptyline was not more effective than placebo in reducing FD symptoms in participants pre-selected based on CYP2D6 genotype, although a biological effect of nortriptyline could not be ruled out. However, effects related to participants' belief appeared to be stronger.
CLINICALTRIALS: gov, Number, NCT03652571.
METHODS: We conducted a multicenter, RCT of patients with FD in primary, secondary, and tertiary care. Sixty-nine participants were randomly assigned to nortriptyline (weeks 1-2: 10 mg; weeks 3-4: 25 mg; weeks 5-12: 50 mg) vs placebo for a 12-week treatment. The primary outcome was clinical response based on a decrease in FD symptoms of at least 30% compared with baseline, in 50% of the last 10 weeks of the treatment period.
RESULTS: The primary outcome showed no significant difference in response for nortriptyline compared with placebo (45% vs 58%; odds ratio [OR], 0.574; 95% confidence interval [CI], 0.211-1.560; P = .276). There was no significant difference in adverse events between the nortriptyline and placebo group. Nortriptyline plasma levels were significantly higher in responders compared with non-responders (13.0 μg/L; interquartile range [IQR], 12.0-16.0 vs 9.0 μg/L; IQR, 8.0-10.5; P = .003). The belief to have received nortriptyline showed a higher response rate than the belief to have received placebo (77% vs 36%; OR, 11.439; 95% CI, 2.138-61.201; P = .004).
CONCLUSIONS: Nortriptyline was not more effective than placebo in reducing FD symptoms in participants pre-selected based on CYP2D6 genotype, although a biological effect of nortriptyline could not be ruled out. However, effects related to participants' belief appeared to be stronger.
CLINICALTRIALS: gov, Number, NCT03652571.